European biotech company Algo Therapeutix announced today that the U.SFood and Drug Administration (FDA) has awarded ATX01 (Amitlin gel) orphan drug for the treatment of erythromemelalgiaErydy limb pain is a rare disease, a plant nervous system disease characterized by elevated skin temperature at the far end of the limb and severe burning painAlthough erythema is thought to be caused by abnormal vascular contraction or dysfunction, the pain of erythema pain is thought to be associated with sodium channel dysfunctionATX01 (Amitlin gel) is mainly targeted at peripheral neuropathy caused by chemotherapyBy applying proprietary high-concentration amitillin gels locally, ATX01 is designed to reach damaged nerve fibers directly in the skin and to avoid systemic side effects of oral and injectable compoundsPreclinical studies have shown that local amitlin has an ananalgesic effect on voltage gated sodium channels Nav1.7, Nav1.8 and Nav1.9, as well as peripheral sensory nerve fibers A beta, A- and CATX01 will enter Phase I clinical development in late 2020 to treat erythema
